ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Medicine / Cardiology
Public health
Medicine / Pharmacology
Biology
Research
Pure sciences
Sports
Chemistry
Veterinary

Languages

Countries
Greece
United Kingdom
Italy
Portugal
Bangladesh
USA
Macedonia
Poland

Years
2020
2019
2018
2017
2016
2014
2013

Filter  
 
14  Articles
1 of 2 pages  |  10  records  |  more records»
Venous thromboembolism is associated with a high morbidity and, if left untreated, may progress to fatal outcome. The standard treatment of venous thromboembolism consists of heparin followed by long-term treatment with a vitamin K antagonist. However, th... see more

We report here the case of a 70 year-old male, lifelong never smoker, who has been admitted to our inpatient Pulmonology clinic for the presence by one month of persistent fever associated in the last seven days with fatigue and mild exertional dyspnea (2... see more

Renal infarction is a rare cause of abdominal pain whose diagnosis is often misunderstood or severely delayed. The difficulty in identifying this time-dependent condition greatly limits the possibilities of therapeutic intervention and determines the loss... see more

For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy that existed to reduce the risk of stroke and thromboembolism until non-vitamin K oral anticoagulants (NOACs). Direct thrombin inhibitor: dabigatran and fact... see more

Cancer is accompanied by an increase of both thrombotic and hemorrhagic complications. Thus, the management of venous thromboembolism (VTE) or atrial fibrillation (AF) presents certain difficulties in oncologic patients. So far, low molecular weight hepar... see more

Over the recent years, new oral anticoagulant agents have been developed and entered the clinical arena, the direct or non-vitamin K oral anticoagulants (NOACs). Although more expensive, these agents have been proven as equivalent or superior to vitamin K... see more

The increasing use of the non-vitamin K oral anticoagulants during the recent years was associated with the need of development of targeted agents that could reverse the anticoagulative activity in cases of severe bleeding episodes or urgent high risk ope... see more

[first paragraph of article]Dear Editor, I read with interest the recent discussion on the ENGAGE-AF trial written by Kaba et al. The authors provide a comprehensive discussion of the novel oral anticoagulant (NOAC), Edoxaban. However, it is importan... see more

Recent trials have presented compelling evidence for the safety and efficacy of the new oral anticoagulants (NOACs) versus warfarin for stroke prevention in patients with atrial fibrillation (AF). The ENGAGE AF-TIMI 48 trial, the biggest of thes... see more

1 of 2 pages  |  10  records  |  more records»